News

March 18, 2020March 18, 2020

Data from Abivax Trial Testing ABX464 Anti-inflammatory for UC Expected by Year’s End

News

Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s financial ... Read more

March 16, 2020March 16, 2020

Immunosuppressive Therapy Does Not Increase Vaginal Cancer Risk, Study Finds

News

Therapies that suppress the immune system do not increase the risk of vulvar or vaginal cancer in women with inflammatory bowel disease (IBD), a new study has found. The study, ... Read more

March 13, 2020March 13, 2020

Inflammation Type Linked to Flares, Hospitalizations in IBD Patients, Study Says

News

People with inflammatory bowel disease (IBD) whose gut inflammation is driven by eosinophils — a type of white blood cells — are less likely to experience disease flares and require ... Read more

March 11, 2020March 11, 2020

In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio

News

Royalty Pharma has bought Massachusetts General Hospital’s (MGH) royalty interest in the inflammatory bowel disease (IBD) therapy Entyvio (vedolizumab) for $94 million. Produced by Millennium Pharmaceuticals, which is part of Takeda, ... Read more

March 9, 2020March 9, 2020

Osteoporosis Twice as High in IBD Patients, Danish Study Finds

News

The risk of osteoporosis is twice as high in people with inflammatory bowel disease (IBD) as in the general population, a Danish study found. The study, “Incidence, risk factors and ... Read more

March 6, 2020March 6, 2020

Innovation Designs Plan for Phase 2 Brilacidin Trial for Ulcerative Colitis

News

The planned brilacidin Phase 2 trial will be conducted in two parts and test several therapy doses, against a placebo, to determine the safety and effectiveness of the investigational oral ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare ... Read more

March 4, 2020March 4, 2020

Panel Recommends European Approval of Entyvio At-Home Injection

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of a subcutaneous (under-the-skin) injection of Entyvio (Vedolizumab), the gut-selective maintenance therapy for ... Read more

March 2, 2020March 2, 2020

Remsima in New Injection Form Shows Safety and Efficacy in Trial

News

A new formulation of CT-P13, a biosimilar of Remicade (infliximab), given as an under-the-skin injection is as safe and effective for people with active Crohn’s disease (CD) and ulcerative colitis (UC) as ... Read more

February 26, 2020February 26, 2020

New Entyvio Formulation – Given as Injection at Home – Leads to Crohn’s Remission After One Year, Takeda Announces

News

Maintenance therapy with Entyvio‘s new formulation as a subcutaneous, or under-the-skin injection (SC) led more people with moderate-to-severe, active Crohn’s disease (CD) to achieve clinical remission after one year, compared ... Read more